Rechallenging Unresectable Hepatocellular Carcinoma with the STRIDE Regimen: A Case Report of Significant AFP Response after Atezolizumab-Bevacizumab Intolerance
This case suggests that rechallenging with the STRIDE regimen may provide significant clinical benefit in HCC patients intolerant to initial ICI therapy. However, further clinical trials are needed to confirm the efficacy and optimal use of ICI rechallenge strategies in HCC.
Authors
- James Doolin (ORCID: https://orcid.org/0000-0002-8109-017X)
- Sugat Adhikari (ORCID: https://orcid.org/0000-0001-6808-1116)
Institutions
- Lahey Medical Center (US)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1159/000546711
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32